Cambient Family Office LLC Makes New Investment in Amgen Inc. $AMGN

Cambient Family Office LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,253 shares of the medical research company’s stock, valued at approximately $737,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Norges Bank acquired a new stake in Amgen in the 4th quarter worth about $2,164,162,000. Capital World Investors increased its stake in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. State Street Corp increased its stake in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Finally, Amundi boosted its position in shares of Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after acquiring an additional 988,856 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Mizuho boosted their target price on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research note on Friday, June 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Finally, UBS Group upped their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $354.42.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by insiders.

Amgen Stock Down 1.2%

Shares of NASDAQ:AMGN opened at $337.60 on Friday. The stock has a 50-day simple moving average of $340.96 and a 200-day simple moving average of $345.81. The stock has a market capitalization of $182.21 billion, a P/E ratio of 23.49, a PEG ratio of 3.43 and a beta of 0.42. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.